European Commission Approves Amneal's XOLAIR Biosimilar Adcomfo
AMRX sits 85% above its 52-week low of $11.39.
Summary
The European Commission granted marketing authorization for Adcomfo (omalizumab), Amneal's biosimilar to XOLAIR, covering severe allergic asthma, CRSwNP and chronic spontaneous urticaria. The asset came with the August 2026 Kashiv acquisition, and this follows the September 2026 CHMP positive opinion plus a March 2026 UK MHRA authorization. Commercialization in Europe sits with ADVANZ PHARMA under its Alvotech partnership, so near-term revenue capture is shared rather than wholly Amneal's. The bigger swing factor is the U.S.: Amneal's BLA for the omalizumab biosimilar is still under FDA review, and that market is where the company books its own sales. Approval lands as Amneal digests Kashiv costs that drove a $21.7 million Q3 net loss despite 10% revenue growth to $863 million and raised 2026 guidance of $3.15B-$3.25B.
At the time of this announcement, AMRX was trading at $21.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $11.39 to $22.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.